MDACC Study No:2005-0601 ( NCT No: NCT00651937)
Title:Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients with Multiple Myeloma or Amyloidosis
Principal Investigator:Nina Shah
Treatment Agent:Melphalan
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn whether higher doses of
stem cells can help to decrease the symptoms that occur after melphalan.
Another goal of the study is to see how the dose of infused stem cells affects
the levels of certain proteins in your blood. Researchers also want to learn
how the dose of stem cells that you receive affects the quality of your life
during the weeks after the transplant procedure.
Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation; Myeloma
Phase of Study:Phase II
Treatment Agents:Melphalan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Four weeks for the autologous transplant,
Supported By:N/A
Return Visit:Monthly for 3 months and at 6 and 12 months post transplant
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nina Shah
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-794-5745
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults